Related references
Note: Only part of the references are listed.Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy
George Mulligan et al.
BLOOD (2014)
International Myeloma Working Group recommendations for global myeloma care
H. Ludwig et al.
LEUKEMIA (2014)
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2013)
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma
Brian A. Walker et al.
BLOOD (2012)
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
Michael Steckel et al.
CELL RESEARCH (2012)
Clinical and biological significance of RAS mutations in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2008)
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma
Martin Kropff et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Share Paper
